Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Risk factors and preventive interventions for Alzheimer disease: state of the science.

Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, Connolly ES Jr, Dunbar-Jacob JM, Granieri EC, McGarry K, Patel D, Trevisan M, Williams JW Jr.

Arch Neurol. 2011 Sep;68(9):1185-90. doi: 10.1001/archneurol.2011.100. Review.

PMID:
21555601
2.

Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life.

Plassman BL, Williams JW Jr, Burke JR, Holsinger T, Benjamin S.

Ann Intern Med. 2010 Aug 3;153(3):182-93. doi: 10.7326/0003-4819-153-3-201008030-00258. Review.

PMID:
20547887
3.

Preventing Alzheimer's disease and cognitive decline.

Williams JW, Plassman BL, Burke J, Benjamin S.

Evid Rep Technol Assess (Full Rep). 2010 Apr;(193):1-727. Review.

4.

Diet and Alzheimer's disease risk factors or prevention: the current evidence.

Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A.

Expert Rev Neurother. 2011 May;11(5):677-708. doi: 10.1586/ern.11.56. Review.

PMID:
21539488
5.

NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.

Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M.

NIH Consens State Sci Statements. 2010 Apr 28;27(4):1-30. Review.

6.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
7.

Screening for speech and language delay in preschool children: systematic evidence review for the US Preventive Services Task Force.

Nelson HD, Nygren P, Walker M, Panoscha R.

Pediatrics. 2006 Feb;117(2):e298-319. Review. Erratum in: Pediatrics. 2006 Jun;117(6):2336-7.

PMID:
16452337
8.

[Alzheimer's disease and treatment of vascular risk factors].

de Leeuw FE, van Norden AG, van der Flier WM, Olde Rikkert MG, Scheltens P.

Ned Tijdschr Geneeskd. 2005 Dec 17;149(51):2844-9. Review. Dutch.

PMID:
16398165
9.

B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review.

Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B.

J Alzheimers Dis. 2010;22(1):205-24. doi: 10.3233/JAD-2010-090940. Review.

PMID:
20847412
10.

The role of Homocysteine as a predictor for coronary heart disease.

L├╝hmann D, Schramm S, Raspe H.

GMS Health Technol Assess. 2007 Nov 9;3:Doc11.

11.

Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan.

Chiang CJ, Yip PK, Wu SC, Lu CS, Liou CW, Liu HC, Liu CK, Chu CH, Hwang CS, Sung SF, Hsu YD, Chen CC, Liu SI, Yan SH, Fong CS, Chang SF, You SL, Chen CJ.

Am J Geriatr Psychiatry. 2007 Sep;15(9):762-71.

PMID:
17623813
12.

[Vascular risk factors and Alzheimer disease risk: epidemiological studies review].

Cowppli-Bony P, Dartigues JF, Orgogozo JM.

Psychol Neuropsychiatr Vieil. 2006 Mar;4(1):47-60. Review. French.

13.

Parkinsonianlike signs and risk of incident Alzheimer disease in older persons.

Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA.

Arch Neurol. 2003 Apr;60(4):539-44.

PMID:
12707067
14.

Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study.

Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S.

Arch Neurol. 2006 Nov;63(11):1551-5.

PMID:
17101823
15.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

16.

Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline.

Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, Bennett DA, Wilson RS, Aggarwal N.

J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1093-9.

17.

Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force.

Wolff T, Witkop CT, Miller T, Syed SB; U.S. Preventive Services Task Force..

Ann Intern Med. 2009 May 5;150(9):632-9. Review.

PMID:
19414843
18.

[Risk factors for cognitive impairment].

Cicconetti P, Riolo N, Priami C, Tafaro L, Ettore E.

Recenti Prog Med. 2004 Nov;95(11):535-45. Review. Italian.

PMID:
15598092
19.

Treatment of vascular risk factors is associated with slower decline in Alzheimer disease.

Deschaintre Y, Richard F, Leys D, Pasquier F.

Neurology. 2009 Sep 1;73(9):674-80. doi: 10.1212/WNL.0b013e3181b59bf3.

PMID:
19720973
20.

Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease.

Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD.

CMAJ. 2008 Feb 26;178(5):548-56. doi: 10.1503/cmaj.070796. Review.

Items per page

Supplemental Content

Support Center